Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.

Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.

Oncotarget. 2019 Sep 3;10(51):5385-5386. doi: 10.18632/oncotarget.27186. eCollection 2019 Sep 3.

2.

Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.

Vlacic G, Hoda MA, Klikovits T, Sinn K, Gschwandtner E, Mohorcic K, Schelch K, Pirker C, Peter-Vörösmarty B, Brankovic J, Dome B, Laszlo V, Cufer T, Rozman A, Klepetko W, Grasl-Kraupp B, Hegedus B, Berger W, Kern I, Grusch M.

Cells. 2019 Sep 16;8(9). pii: E1091. doi: 10.3390/cells8091091.

3.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S.

Gastroenterology. 2019 Sep;157(3):760-776. doi: 10.1053/j.gastro.2019.05.001. Epub 2019 May 4.

PMID:
31063779
4.

FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer.

Harpain F, Ahmed MA, Hudec X, Timelthaler G, Jomrich G, Müllauer L, Selzer E, Dörr W, Bergmann M, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B, Silberhumer GR.

J Cancer Res Clin Oncol. 2019 Jan;145(1):77-86. doi: 10.1007/s00432-018-2757-7. Epub 2018 Oct 1.

5.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
6.

Model Prediction and Validation of an Order Mechanism Controlling the Spatiotemporal Phenotype of Early Hepatocellular Carcinoma.

Hoehme S, Bertaux F, Weens W, Grasl-Kraupp B, Hengstler JG, Drasdo D.

Bull Math Biol. 2018 May;80(5):1134-1171. doi: 10.1007/s11538-017-0375-1. Epub 2018 Mar 22.

PMID:
29568983
7.

Mesenchyme-derived factors enhance preneoplastic growth by non-genotoxic carcinogens in rat liver.

Nejabat M, Riegler T, Reitinger T, Subosits S, Römer M, Eichner J, Bilban M, Zell A, Huber WW, Schulte-Hermann R, Grasl-Kraupp B.

Arch Toxicol. 2018 Feb;92(2):953-966. doi: 10.1007/s00204-017-2080-0. Epub 2017 Dec 21.

8.

FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.

Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, Meindl D, Pirker C, Hegedus B, Marian B, Holzmann K, Grasl-Kraupp B, Heffeter P, Berger W, Grusch M.

Oncotarget. 2017 Sep 23;8(50):87750-87762. doi: 10.18632/oncotarget.21184. eCollection 2017 Oct 20.

9.

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis.

Erdem ZN, Schwarz S, Drev D, Heinzle C, Reti A, Heffeter P, Hudec X, Holzmann K, Grasl-Kraupp B, Berger W, Grusch M, Marian B.

Transl Oncol. 2017 Jun;10(3):332-339. doi: 10.1016/j.tranon.2017.02.004. Epub 2017 Mar 22.

10.

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.

Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rohr-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrié N, Nault JC, Ziol M, Zucman-Rossi J.

Clin Cancer Res. 2017 Aug 1;23(15):4364-4375. doi: 10.1158/1078-0432.CCR-16-3118. Epub 2017 Feb 28.

11.

Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.

Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.

Oncotarget. 2016 Oct 25;7(43):69976-69990. doi: 10.18632/oncotarget.12099. Erratum in: Oncotarget. 2019 Sep 03;10(51):5385-5386.

12.

Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.

Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabó P, Heffeter P, Lang I, Cichna-Markl M, Grasl-Kraupp B, Marian B, Grusch M, Kubicek S, Szakács G, Berger W.

Oncotarget. 2016 Aug 2;7(31):50161-50179. doi: 10.18632/oncotarget.10324.

13.

Proinflammatory mesenchymal effects of the non-genotoxic hepatocarcinogen phenobarbital: a novel mechanism of antiapoptosis and tumor promotion.

Riegler T, Nejabat M, Eichner J, Stiebellehner M, Subosits S, Bilban M, Zell A, Huber WW, Schulte-Hermann R, Grasl-Kraupp B.

Carcinogenesis. 2015 Dec;36(12):1521-30. doi: 10.1093/carcin/bgv135. Epub 2015 Sep 16.

PMID:
26378027
14.

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

Paur J, Nika L, Maier C, Moscu-Gregor A, Kostka J, Huber D, Mohr T, Heffeter P, Schrottmaier WC, Kappel S, Kandioler D, Holzmann K, Marian B, Berger W, Grusch M, Grasl-Kraupp B.

Hepatology. 2015 Dec;62(6):1767-78. doi: 10.1002/hep.28023. Epub 2015 Oct 16.

PMID:
26235436
15.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

PMID:
25188816
16.

Superoxide deficiency attenuates promotion of hepatocarcinogenesis by cytotoxicity in NADPH oxidase knockout mice.

Parzefall W, Freiler C, Lorenz O, Koudelka H, Riegler T, Nejabat M, Kainzbauer E, Grasl-Kraupp B, Schulte-Hermann R.

Arch Toxicol. 2015 Aug;89(8):1383-93. doi: 10.1007/s00204-014-1298-3. Epub 2014 Sep 3.

PMID:
25182417
17.

Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.

Gauglhofer C, Paur J, Schrottmaier WC, Wingelhofer B, Huber D, Naegelen I, Pirker C, Mohr T, Heinzle C, Holzmann K, Marian B, Schulte-Hermann R, Berger W, Krupitza G, Grusch M, Grasl-Kraupp B.

Carcinogenesis. 2014 Oct;35(10):2331-8. doi: 10.1093/carcin/bgu151. Epub 2014 Jul 16.

PMID:
25031272
18.

Phenobarbital induces cell cycle transcriptional responses in mouse liver humanized for constitutive androstane and pregnane x receptors.

Luisier R, Lempiäinen H, Scherbichler N, Braeuning A, Geissler M, Dubost V, Müller A, Scheer N, Chibout SD, Hara H, Picard F, Theil D, Couttet P, Vitobello A, Grenet O, Grasl-Kraupp B, Ellinger-Ziegelbauer H, Thomson JP, Meehan RR, Elcombe CR, Henderson CJ, Wolf CR, Schwarz M, Moulin P, Terranova R, Moggs JG.

Toxicol Sci. 2014 Jun;139(2):501-11. doi: 10.1093/toxsci/kfu038. Epub 2014 Apr 1.

PMID:
24690595
19.

Phenobarbital induces alterations in the proteome of hepatocytes and mesenchymal cells of rat livers.

Klepeisz P, Sagmeister S, Haudek-Prinz V, Pichlbauer M, Grasl-Kraupp B, Gerner C.

PLoS One. 2013 Oct 24;8(10):e76137. doi: 10.1371/journal.pone.0076137. eCollection 2013.

20.

Myofibroblasts are important contributors to human hepatocellular carcinoma: evidence for tumor promotion by proteome profiling.

Slany A, Haudek-Prinz V, Zwickl H, Stättner S, Grasl-Kraupp B, Gerner C.

Electrophoresis. 2013 Dec;34(24):3315-25. doi: 10.1002/elps.201300326. Epub 2013 Nov 5.

PMID:
24115093
21.

Protective effects of coffee against induction of DNA damage and pre-neoplastic foci by aflatoxin B₁.

Ferk F, Huber WW, Grasl-Kraupp B, Speer K, Buchmann S, Bohacek R, Mišík M, Edelbauer L, Knasmüller S.

Mol Nutr Food Res. 2014 Feb;58(2):229-38. doi: 10.1002/mnfr.201300154. Epub 2013 Aug 30.

PMID:
24039089
22.

Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Heinzle C, Erdem Z, Paur J, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Curr Pharm Des. 2014;20(17):2881-98. Review.

23.

Food-derived peroxidized fatty acids may trigger hepatic inflammation: a novel hypothesis to explain steatohepatitis.

Böhm T, Berger H, Nejabat M, Riegler T, Kellner F, Kuttke M, Sagmeister S, Bazanella M, Stolze K, Daryabeigi A, Bintner N, Murkovic M, Wagner KH, Schulte-Hermann R, Rohr-Udilova N, Huber W, Grasl-Kraupp B.

J Hepatol. 2013 Sep;59(3):563-70. doi: 10.1016/j.jhep.2013.04.025. Epub 2013 May 9.

PMID:
23665282
24.

Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.

Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stättner S, Karner J, Klimpfinger M, Wrba F, Reti A, Hegedus B, Baierl A, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Cancer Res. 2012 Nov 15;72(22):5767-77. doi: 10.1158/0008-5472.CAN-11-3654. Epub 2012 Sep 12.

25.

The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells.

Losert A, Lötsch D, Lackner A, Koppensteiner H, Peter-Vörösmarty B, Steiner E, Holzmann K, Grunt T, Schmid K, Marian B, Grasl-Kraupp B, Schulte-Hermann R, Krupitza G, Berger W, Grusch M.

Cancer Lett. 2012 Jun 28;319(2):164-172. doi: 10.1016/j.canlet.2012.01.002. Epub 2012 Jan 17.

PMID:
22261339
26.

Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma.

Rohr-Udilova N, Sieghart W, Eferl R, Stoiber D, Björkhem-Bergman L, Eriksson LC, Stolze K, Hayden H, Keppler B, Sagmeister S, Grasl-Kraupp B, Schulte-Hermann R, Peck-Radosavljevic M.

Hepatology. 2012 Apr;55(4):1112-21. doi: 10.1002/hep.24808.

PMID:
22105228
27.

Potent protection of gallic acid against DNA oxidation: results of human and animal experiments.

Ferk F, Chakraborty A, Jäger W, Kundi M, Bichler J, Mišík M, Wagner KH, Grasl-Kraupp B, Sagmeister S, Haidinger G, Hoelzl C, Nersesyan A, Dušinská M, Simić T, Knasmüller S.

Mutat Res. 2011 Oct 1;715(1-2):61-71. doi: 10.1016/j.mrfmmm.2011.07.010. Epub 2011 Jul 30.

PMID:
21827773
28.

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Metzner T, Bedeir A, Held G, Peter-Vörösmarty B, Ghassemi S, Heinzle C, Spiegl-Kreinecker S, Marian B, Holzmann K, Grasl-Kraupp B, Pirker C, Micksche M, Berger W, Heffeter P, Grusch M.

J Invest Dermatol. 2011 Oct;131(10):2087-95. doi: 10.1038/jid.2011.177. Epub 2011 Jul 14.

29.

Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?

Frost K, Seir K, Lackner A, Grusch M, Grasl-Kraupp B, Schulte-Hermann R, Rodgarkia-Dara C.

Br J Cancer. 2011 Apr 12;104(8):1303-12. doi: 10.1038/bjc.2011.53. Epub 2011 Mar 15.

30.

Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.

Heinzle C, Sutterlüty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B.

Expert Opin Ther Targets. 2011 Jul;15(7):829-46. doi: 10.1517/14728222.2011.566217. Epub 2011 Mar 7. Review.

PMID:
21375471
31.

Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.

Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stättner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B.

Hepatology. 2011 Mar;53(3):854-64. doi: 10.1002/hep.24099. Epub 2011 Feb 11.

PMID:
21319186
32.

Xanthohumol, a prenylated flavonoid contained in beer, prevents the induction of preneoplastic lesions and DNA damage in liver and colon induced by the heterocyclic aromatic amine amino-3-methyl-imidazo[4,5-f]quinoline (IQ).

Ferk F, Huber WW, Filipic M, Bichler J, Haslinger E, Misík M, Nersesyan A, Grasl-Kraupp B, Zegura B, Knasmüller S.

Mutat Res. 2010 Sep 10;691(1-2):17-22. doi: 10.1016/j.mrfmmm.2010.06.006. Epub 2010 Jun 12.

PMID:
20547166
33.

Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.

Sonvilla G, Allerstorfer S, Heinzle C, Stättner S, Karner J, Klimpfinger M, Wrba F, Fischer H, Gauglhofer C, Spiegl-Kreinecker S, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Br J Cancer. 2010 Mar 30;102(7):1145-56. doi: 10.1038/sj.bjc.6605596. Epub 2010 Mar 16.

34.

Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence.

Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhör T, Peck-Radosavljevic M, Beug H, Mikulits W.

Am J Pathol. 2010 Jan;176(1):472-81. doi: 10.2353/ajpath.2010.090300. Epub 2009 Dec 11.

35.

Proteomics reveals acute pro-inflammatory and protective responses in rat Kupffer cells and hepatocytes after chemical initiation of liver cancer and after LPS and IL-6.

Lorenz O, Parzefall W, Kainzbauer E, Wimmer H, Grasl-Kraupp B, Gerner C, Schulte-Hermann R.

Proteomics Clin Appl. 2009 Aug;3(8):947-67. doi: 10.1002/prca.200800173.

PMID:
21136998
36.

NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.

Macheiner D, Gauglhofer C, Rodgarkia-Dara C, Grusch M, Brachner A, Bichler C, Kandioler D, Sutterlüty H, Mikulits W, Schulte-Hermann R, Grasl-Kraupp B.

Cancer Res. 2009 Jan 1;69(1):235-42. doi: 10.1158/0008-5472.CAN-08-2144.

37.

HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis.

Sagmeister S, Drucker C, Losert A, Grusch M, Daryabeigi A, Parzefall W, Rohr-Udilova N, Bichler C, Smedsrød B, Kandioler D, Grünberger T, Wrba F, Schulte-Hermann R, Grasl-Kraupp B.

J Hepatol. 2008 Dec;49(6):955-64. doi: 10.1016/j.jhep.2008.06.031. Epub 2008 Oct 7.

PMID:
18929421
38.

Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.

Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, Gauglhofer C, Marian B, Micksche M, Berger W.

Mol Cancer Ther. 2008 Oct;7(10):3408-19. doi: 10.1158/1535-7163.MCT-08-0444.

39.

Use of four new human-derived liver-cell lines for the detection of genotoxic compounds in the single-cell gel electrophoresis (SCGE) assay.

Winter HK, Ehrlich VA, Grusch M, Lackner A, Schulte-Hermann R, Grasl-Kraupp B, Mikulits W, Knasmüller S.

Mutat Res. 2008 Dec 8;657(2):133-9. doi: 10.1016/j.mrgentox.2008.08.012. Epub 2008 Aug 26.

PMID:
18790080
40.

New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis.

Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B.

Br J Cancer. 2008 Jul 8;99(1):151-9. doi: 10.1038/sj.bjc.6604440.

41.

FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.

Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Gauglhofer C, Setinek U, Czech T, Marosi C, Buchroithner J, Pichler J, Silye R, Mohr T, Holzmann K, Grasl-Kraupp B, Marian B, Grusch M, Fischer J, Micksche M, Berger W.

Oncogene. 2008 Jul 10;27(30):4180-90. doi: 10.1038/onc.2008.61. Epub 2008 Mar 24.

42.

Lipid hydroperoxides from processed dietary oils enhance growth of hepatocarcinoma cells.

Rohr-Udilova NV, Stolze K, Sagmeister S, Nohl H, Schulte-Hermann R, Grasl-Kraupp B.

Mol Nutr Food Res. 2008 Mar;52(3):352-9. doi: 10.1002/mnfr.200700149.

PMID:
18293301
43.

FGF18 in colorectal tumour cells: autocrine and paracrine effects.

Sonvilla G, Allerstorfer S, Stättner S, Karner J, Klimpfinger M, Fischer H, Grasl-Kraupp B, Holzmann K, Berger W, Wrba F, Marian B, Grusch M.

Carcinogenesis. 2008 Jan;29(1):15-24. Epub 2007 Sep 22.

PMID:
17890768
44.

Cytotoxicity of the novel spin trapping compound 5-ethoxycarbonyl-3,5-dimethyl-pyrroline N-oxide (3,5-EDPO) and its derivatives.

Rohr-Udilova N, Stolze K, Sagmeister S, Parzefall W, Marian B, Nohl H, Schulte-Hermann R, Grasl-Kraupp B.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5698-703. Epub 2007 Aug 19.

PMID:
17804223
45.

Divide and conquer: rat liver tissue proteomics based on the analysis of purified constituents.

Teufelhofer O, Parzefall W, Elbling L, Kainzbauer E, Grasl-Kraupp B, Zielinski C, Schulte-Hermann R, Gerner C.

Electrophoresis. 2006 Oct;27(20):4112-20.

PMID:
17054093
46.

Deregulation of the activin/follistatin system in hepatocarcinogenesis.

Grusch M, Drucker C, Peter-Vörösmarty B, Erlach N, Lackner A, Losert A, Macheiner D, Schneider WJ, Hermann M, Groome NP, Parzefall W, Berger W, Grasl-Kraupp B, Schulte-Hermann R.

J Hepatol. 2006 Nov;45(5):673-80. Epub 2006 Jul 28.

PMID:
16935389
47.

NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma.

Macheiner D, Heller G, Kappel S, Bichler C, Stättner S, Ziegler B, Kandioler D, Wrba F, Schulte-Hermann R, Zöchbauer-Müller S, Grasl-Kraupp B.

J Hepatol. 2006 Jul;45(1):81-9. Epub 2006 Feb 7.

PMID:
16516329
48.

Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis.

Drucker C, Parzefall W, Teufelhofer O, Grusch M, Ellinger A, Schulte-Hermann R, Grasl-Kraupp B.

Carcinogenesis. 2006 Jan;27(1):152-61. Epub 2005 Aug 4.

PMID:
16081514
49.

A novel technique to specifically analyze the secretome of cells and tissues.

Zwickl H, Traxler E, Staettner S, Parzefall W, Grasl-Kraupp B, Karner J, Schulte-Hermann R, Gerner C.

Electrophoresis. 2005 Jul;26(14):2779-85.

PMID:
15966010
50.

Apoptosis in stages of mouse hepatocarcinogenesis: failure to counterbalance cell proliferation and to account for strain differences in tumor susceptibility.

Bursch W, Chabicovsky M, Wastl U, Grasl-Kraupp B, Bukowska K, Taper H, Schulte-Hermann R.

Toxicol Sci. 2005 May;85(1):515-29. Epub 2005 Feb 23.

PMID:
15728704

Supplemental Content

Loading ...
Support Center